# reload+after+2024-01-21 03:44:01.141542
address1§Azrieli Center
address2§Building D 26 Harokmim Street
city§Holon
zip§5885849
country§Israel
phone§972 3 765 8585
fax§972 3 765 8555
website§https://cgen.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.
fullTimeEmployees§69
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Anat  Cohen-Dayag Ph.D.', 'age': 56, 'title': 'CEO, President & Director', 'yearBorn': 1967, 'fiscalYear': 2022, 'totalPay': 796519, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Zurit  Levine Ph.D.', 'age': 55, 'title': 'Senior Vice President of Technology Innovation', 'yearBorn': 1968, 'fiscalYear': 2022, 'totalPay': 345697, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Henry  Adewoye M.D.', 'age': 58, 'title': 'Senior VP & Chief Medical Officer', 'yearBorn': 1965, 'fiscalYear': 2022, 'totalPay': 605291, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Pierre  Ferre Ph.D.', 'age': 46, 'title': 'Vice President of Preclinical Development', 'yearBorn': 1977, 'fiscalYear': 2022, 'totalPay': 415100, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Alberto  Sessa', 'age': 61, 'title': 'Chief Financial Officer', 'yearBorn': 1962, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Eran  Ophir Ph.D.', 'age': 45, 'title': 'Chief Scientific Officer', 'yearBorn': 1978, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Yvonne  Naughton', 'title': 'Head of Investor Relations & Corporate Communications', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Eran Ben Dor', 'title': 'General Counsel & Corporate Secretary', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Dorit  Amitay', 'age': 55, 'title': 'Vice President of Human Resources', 'yearBorn': 1968, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Yaron  Turpaz M.B.A., Ph.D.', 'age': 52, 'title': 'Senior VP & Senior Advisor of Data and Informatics Solutions', 'yearBorn': 1971, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§2.803
priceToSalesTrailing12Months§23.234005
currency§USD
dateShortInterest§1702598400
forwardEps§-0.33
exchange§NCM
quoteType§EQUITY
shortName§Compugen Ltd.
longName§Compugen Ltd.
firstTradeDateEpochUtc§966000600
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§1985262d-ab80-3c43-a2e1-6782924ab738
gmtOffSetMilliseconds§-18000000
targetHighPrice§7.0
targetLowPrice§4.0
targetMeanPrice§5.0
targetMedianPrice§4.0
recommendationMean§1.3
recommendationKey§strong_buy
numberOfAnalystOpinions§3
quickRatio§5.809
grossMargins§0.87
ebitdaMargins§0.0
trailingPegRatio§None
